SCHEMBL1665546

SCHEMBL1665546

COc1ccc(N2CCNCC2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.56
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
HTR3A P46098 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
POLB P06746 1/20 0.49
GAA P10253 1/20 0.48
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
RAB9A P51151 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
NPC1 O15118 2/20 0.43
HTR1A P08908 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1584077 0.98 ADRB1 (0.54) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL1663489 0.83 ADRB1 (0.59) ADRB1HTR3ASLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL1584087 0.82 ADRB1 (0.57) ADRB1HTR3ASLC6A2SLC6A4SLC6A3
SCHEMBL8286227 0.81 ADRB1 (0.52) ADRB1SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL18553759 0.81 LTA4H (0.58) SLC6A2SLC6A4SLC6A3MAPTHTR1A
SCHEMBL3656969 0.80 SLC6A2 (0.50) POLBSLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL4396319 0.80 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3MAPKAPK2
SCHEMBL85663 0.80 SLC6A2 (0.50) POLBGAASLC6A2SLC6A4SLC6A3
SCHEMBL13362047 0.79 SLC6A2 (0.48) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL13664706 0.79 SLC6A2 (0.58) ADRB1HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9339503-B2 Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors MERCK PATENT GMBH (DE) 2016-05-17 US disclosed
EP-2812323-B1 TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS MERCK PATENT GMBH (DE) 2016-04-06 EP disclosed
US-20150025071-A1 TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
EP-2812323-A1 TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS Merck Patent GmbH (DE) 2014-12-17 EP disclosed
WO-2013117288-A1 TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS MERCK PATENT GMBH (DE) 2013-08-15 WO disclosed
WO-2011050284-A1 PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-04-28 WO disclosed
WO-2010064769-A1 2-PIPERAZINO-4,5-DOUBLE SUBSTITUTION-1,3-THIAZOLE DERIVATIVE AND METHOD OF PREPARING THE SAME, AND THERAPEUTIC AGENT CONTAINING THE SAME AS ITS ACTIVE INGREDIENT FOR DISEASES RELATED TO INFLAMMATION CAUSED BY SPC RECEPTOR ACTIVITY 한국화학연구원 (KR) 2010-06-10 WO disclosed
EP-0126480-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025071-A1 TETRAHYDRO-QUINAZOLINONE DERIVATIVES AS TANK AND PARP INHIBITORS TNKS, PARP1, PARP11 ADRB1 2900/4885HTR3E 1233/4885HTR3B 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.